As of September 29, 2026, Monte Rosa Therapeutics's top three insider holders are Ali Behbahani (Director, 6.69Mn shares), Venture Capital Vi, L.P. Versant (TenPercentOwner, 5.65Mn shares), Markus Warmuth (President Ceo, 585.04K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ali Behbahani | Director | 0 | 6,692,298 | 6,692,298 | 50.6% | 06 Jul, 2026 |
| 2 | Venture Capital Vi, L.P. Versant | TenPercentOwner | 4,079,469 | 1,573,453 | 5,652,922 | 42.7% | 30 Oct, 2024 |
| 3 | Markus Warmuth | President Ceo | 585,038 | 0 | 585,038 | 4.4% | 17 Jul, 2026 |
| 4 | Sharon Townson | Chief Scientific Officer | 67,845 | 0 | 67,845 | 0.5% | 07 Jul, 2026 |
| 5 | Jennifer Champoux | Chief Operating Officer | 62,371 | 0 | 62,371 | 0.5% | 16 Jul, 2026 |
| 6 | Filip Janku | Chief Medical Officer | 60,612 | 0 | 60,612 | 0.5% | 01 Jul, 2026 |
| 7 | Philip Nickson | Chief Business Legal Officer | 55,000 | 0 | 55,000 | 0.4% | 10 Apr, 2026 |
| 8 | Matthew Bowen | Principal Accounting Officer | 25,904 | 0 | 25,904 | 0.2% | 07 Apr, 2026 |
| 9 | Edmund Dunn | Principal Accounting Officer | 22,554 | 0 | 22,554 | 0.2% | 05 Mar, 2026 |
| 10 | Chandra P. Leo | Director | 10,000 | 0 | 10,000 | 0.1% | 25 Mar, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 16 Jul, 2026 | Markus Warmuth | President Ceo | Disposed S | 9,500 | $23.18 | $220.22K | 585,038 | Direct |
| 15 Jul, 2026 | Jennifer Champoux | Chief Operating Officer | Acquired M | 4,351 | $3.98 | $17.32K | 66,722 | Direct |
| 15 Jul, 2026 | Jennifer Champoux | Chief Operating Officer | Disposed S | 4,351 | $23.38 | $101.73K | 62,371 | Direct |
| 15 Jul, 2026 | Jennifer Champoux | Chief Operating Officer | Disposed M | 4,351 | $0.00 | $0 | 26,947 | Direct |
| 06 Jul, 2026 | Sharon Townson | Chief Scientific Officer | Acquired M | 6,000 | $6.14 | $36.84K | 73,845 | Direct |
| 06 Jul, 2026 | Sharon Townson | Chief Scientific Officer | Disposed S | 5,600 | $23.25 | $130.20K | 68,245 | Direct |
| 06 Jul, 2026 | Sharon Townson | Chief Scientific Officer | Disposed S | 400 | $24.13 | $9.65K | 67,845 | Direct |
| 06 Jul, 2026 | Sharon Townson | Chief Scientific Officer | Disposed M | 6,000 | $0.00 | $0 | 197,290 | Direct |
| 01 Jul, 2026 | Ali Behbahani | Director | Disposed J | 1,000,000 | $0.00 | $0 | 6,692,298 | Indirect |
| 01 Jul, 2026 | Ali Behbahani | Director | Acquired J | 15,000 | $0.00 | $0 | 15,000 | Indirect |
| 01 Jul, 2026 | Ali Behbahani | Director | Disposed J | 15,000 | $0.00 | $0 | 0 | Indirect |
| 30 Jun, 2026 | Filip Janku | Chief Medical Officer | Acquired M | 5,407 | $13.41 | $72.51K | 66,019 | Direct |
| 30 Jun, 2026 | Filip Janku | Chief Medical Officer | Disposed S | 5,407 | $24.50 | $132.47K | 60,612 | Direct |
| 30 Jun, 2026 | Filip Janku | Chief Medical Officer | Disposed M | 5,407 | $0.00 | $0 | 81,093 | Direct |
| 29 Jun, 2026 | Filip Janku | Chief Medical Officer | Acquired M | 6,000 | $7.56 | $45.36K | 65,992 | Direct |
| 29 Jun, 2026 | Anthony M. Manning | Director | Acquired M | 10,000 | $4.16 | $41.60K | 10,000 | Direct |
| 29 Jun, 2026 | Anthony M. Manning | Director | Disposed S | 10,000 | $23.11 | $231.10K | 0 | Direct |
| 29 Jun, 2026 | Filip Janku | Chief Medical Officer | Disposed S | 6,000 | $22.95 | $137.70K | 59,992 | Direct |
| 29 Jun, 2026 | Filip Janku | Chief Medical Officer | Disposed M | 6,000 | $0.00 | $0 | 60,000 | Direct |
| 29 Jun, 2026 | Anthony M. Manning | Director | Disposed M | 10,000 | $0.00 | $0 | 2,100 | Direct |